Related Experiment Video

Updated: Aug 13, 2026

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)
12:18

Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus (MRSA)

Published on: February 10, 2011

[Community acquired pneumonia in children]

Catherine Weil-Olivier1

  • 1Service de pédiatrie générale, hôpital Louis Mourier, 92700 Colombes. c.weilolivier@lmr.ap-hop-paris.fr

La Revue Du Praticien
|October 16, 2003
PubMed

Insights

Community acquired pneumonia is challenging to diagnose in young children, often requiring chest X-rays. Early antibiotic treatment and vaccination strategies are crucial for managing pediatric pneumonia.

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Respiratory Medicine

Context:

  • Community-acquired pneumonia (CAP) constitutes a significant portion of pediatric respiratory infections.
  • Diagnosis in infants and toddlers is complicated by non-specific symptoms like fever.
  • Typical pneumonia signs are infrequent, necessitating imaging for confirmation.

Purpose:

  • To outline diagnostic challenges and management strategies for community-acquired pneumonia in children.
  • To highlight the role of epidemiological data and risk factors in clinical decision-making.
  • To discuss the impact of vaccination on antibiotic use for pediatric pneumonia.

Summary:

  • Chest radiography is essential for confirming pneumonia, especially in children under two years, or when other diagnoses are suspected.
  • Identifying risk factors and severity criteria aids in hospital admission decisions.
  • Etiological agents vary by age, with viruses and pneumococcus predominant in younger children, and bacterial pathogens like Mycoplasma pneumoniae and Chlamydia pneumoniae emerging in older children.

Impact:

  • Empirical antibiotic therapy should be initiated promptly, guided by age, local epidemiology, and disease severity.
  • Clinical reassessment within 48-72 hours is mandatory to adjust treatment.
  • The widespread use of the 7-valent conjugate anti-pneumococcal vaccine is expected to alter antibiotic prescribing patterns for pediatric pneumonia.

More Related Videos

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria11:32

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria

Published on: February 23, 2014

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia04:32

Murine Oropharyngeal Aspiration Model of Ventilator-associated and Hospital-acquired Bacterial Pneumonia

Published on: June 28, 2018

Related Concept Videos

Pneumonia I: Introduction01:30

Pneumonia I: Introduction

Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
Pneumonia I: Introduction01:29

Pneumonia I: Introduction

Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...